Ishita Drugs and Industries (BSE: ISHITADR) had a P/E of 30.1× on 6 Nov 2026, and the shares are 22% below their 52-week high. It earns ROCE of 9.6% and ROE of 6.2%, and sales and net profit grew 6.7% and 10% a year over 3 years. The company has almost no debt. It is a small-cap company with a market cap of ₹21 Cr; the shares rose 10% over the past year.
- ₹76.60
- ₹76.60
- ₹71.00
- ₹77.99
- 6
Health check
- ReturnsModest
+10.2% over the past year.
- Price tagNo peers
P/E 30.1, with no peers to compare.
- GrowthSteady
Sales +6.7%, profit +10.5% a year over 3 years.
- ProfitabilityWeak
ROCE 9.6%.
- Balance sheetSolid
Practically debt-free.
- Red flags3 to check
Return on equity is low at 6.2%.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹21 Cr
- Small cap
- P/E
- 30.1
- Price to book
- 1.77
- Book value ₹40.16
- Dividend yield
- 0.00%
- ROE
- 6.2%
- Return on equity
- ROCE
- 9.6%
- Return on capital employed
- Debt to equity
- 0.00
- Debt ₹0.01 Cr
- EPS (TTM)
- ₹2.36
- OPM (TTM)
- 5.9%
- Net margin 5.8%
- Sales growth
- −41.8%
- Latest quarter vs a year ago
- Profit growth
- −23.9%
- Latest quarter vs a year ago
- Price to sales
- 1.71
- EV/EBITDA 18.8
Strengths and risks
Strengths
- Practically debt-free.
Risks to check
- Return on equity is low at 6.2%.
- Quarterly profit down 23.9% on a year ago.
- Quarterly sales down 41.8% on a year ago.
About Ishita Drugs and Industries
Ishita Drugs and Industries Limited engages in the manufacture and sale of active pharma ingredients (APIs), fine chemicals, drug intermediates, and excipients in India and internationally. The company offers Active Pharma Ingredients, such as sulfa drugs/sulfonamides, vitamins, fluoro quinolones, antibiotics, anthelmintics, iodides and citrates, food additives/excipients, and others. It also provides contract manufacturing services for various drug…
- Headquarters
- Ahmedabad
- Employees
- 17
- Sector
- Healthcare
- ISIN
- INE806D01016
- Website
- ishitadrugs.com
Price range
- Avg volume (3M)
- 1.7K
- 1-year return
- plus 10.2%
- From 52-week high
- minus 21.8%
Peers
We couldn’t find listed peers for this company.
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 5.4 | 3.1 | 3.1 | 3.1 | 3.1 | |
| 5.1 | 2.9 | 3 | 3 | 2.8 | |
| 0.3 | 0.2 | 0.1 | 0.1 | 0.3 | |
| 6.4% | 6.1% | 4.4% | 3.1% | 10.1% | |
| 0.1 | 0.1 | 0.1 | 0.2 | 0 | |
| 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | |
| 0.4 | 0.2 | 0.2 | 0.3 | 0.3 | |
| 21.9% | 35.3% | 19.1% | 36.4% | 23.3% | |
| 0.3 | 0.1 | 0.2 | 0.2 | 0.2 | |
| 1.01 | 0.48 | 0.52 | 0.59 | 0.77 |
Profit & loss
- Sales CAGR 3Y
- +6.7%
- Profit CAGR 3Y
- +10.5%
- EPS CAGR 3Y
- +10.4%
- ROE
- 6.2%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 12.1 | 15.2 | 15 | 14.7 | |
| – | +25.8% | minus 1.3% | minus 2.2% | |
| 11.3 | 14.3 | 14 | 13.9 | |
| 0.8 | 0.9 | 1 | 0.8 | |
| 6.3% | 6.0% | 6.7% | 5.2% | |
| 0.2 | 0.3 | 0.3 | 0.5 | |
| 0 | 0.1 | 0 | 0 | |
| 0.1 | 0.1 | 0.1 | 0.1 | |
| 0.8 | 1 | 1.2 | 1.1 | |
| 25.9% | 24.2% | 24.8% | 27.9% | |
| 0.6 | 0.7 | 0.9 | 0.8 | |
| – | +29.6% | +16.0% | minus 10.3% | |
| 1.93 | 2.50 | 2.90 | 2.60 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 3 | 3 | 3 | 3 | |
| 6.2 | 6.9 | 7.8 | 8.6 | |
| 1 | – | 3.9 | 0.1 | |
| 1.3 | 0.9 | 1.6 | 1 | |
| 11.4 | 10.8 | 16.3 | 12.6 | |
| 0.9 | 0.8 | 0.9 | 2.6 | |
| – | – | – | 1.7 | |
| 0.3 | 0.3 | 0.4 | 0.4 | |
| 6.6 | 7.9 | 8.3 | 6.8 | |
| 3.7 | 1.9 | 6.7 | 1.1 | |
| 11.4 | 10.8 | 16.3 | 12.6 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −2.9 | 2.1 | −3.6 | 3.9 | |
| 0.6 | 0.1 | −0.7 | −2.2 | |
| 1 | −0.9 | 4.3 | −3.8 | |
| −1.3 | 1.4 | 0 | −2.1 | |
| −0.1 | −0 | −0.2 | −1.9 | |
| −3 | 2.1 | −3.8 | 2.1 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.